Association between plasma proANP and hyperuricemia in Chinese Han women: a cross-sectional study

Zhengbao Zhu; Qiu Zhang; Hao Peng; Chongke Zhong; Yan Liu; Xinfeng Huangfu; Yunfan Tian; Xiangqin Chao; Jianhua Jin; Yonghong Zhang

doi:10.1515/cclm-2016-0503

Article

Association between plasma proANP and hyperuricemia in Chinese Han women: a cross-sectional study

Zhengbao Zhu , Qiu Zhang , Hao Peng , Chongke Zhong , Yan Liu , Xinfeng Huangfu , Yunfan Tian , Xiangqin Chao , Jianhua Jin and Yonghong Zhang

Published/Copyright: January 11, 2017

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 55 Issue 8

Abstract

Background:

Association between pro-atrial natriuretic peptide (proANP) and hyperuricemia has not yet been investigated in population. This study aimed to examine the association in Chinese Han women.

Methods:

We measured plasma proANP, serum uric acid, and other traditional biomarkers in 1360 women older than 30 years residing in the Gusu district of Suzhou City. Association between plasma proANP and hyperuricemia was analyzed in women aged ≥45 years and those aged <45 years, respectively.

Results:

In women aged ≥45 years, the odds ratio (OR) [95% confidence interval (CI)] of hyperuricemia with high proANP (over the median) was 0.57 (0.34–0.97) compared to those with low proANP (p=0.040). After adjustment for age and other potential covariates, a high plasma proANP was associated with a decreased risk of hyperuricemia in women aged ≥45 years (OR 0.40; 95% CI, 0.19–0.84), when the highest and lowest categories were compared. In contrast, there was no association between plasma proANP and hyperuricemia in women aged <45 years. We did not observe a significant interaction between age and proANP (p_interaction=0.113). Sensitivity analyses further confirmed these age-specific findings.

Conclusions:

Plasma proANP was significantly and inversely associated with hyperuricemia in Chinese Han women aged ≥45 years. This study suggests that an increased plasma proANP should be a protective factor of hyperuricemia among middle-aged and old women.

Keywords: Chinese; cross-sectional study; hyperuricemia; plasma proANP; serum uric acid

Corresponding author: Yonghong Zhang, MD, PhD, Department of Epidemiology, School of Public Health, Medical College of Soochow University, 199 Renai Road, Industrial Park District, 215123 Suzhou, P.R. China, Phone/Fax: +86-512-6588-0078

aZhengbao Zhu and Qiu Zhang contributed equally to this work.

Acknowledgments

We are deeply appreciative of the participants in this study, and would like to thank all staffs for their support and assistance.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: The study is supported by a Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions of China, and the Suzhou Science and Technology Project (No. SS0910 and No. SS201333).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Vazquez-Mellado J, Alvarez Hernandez E, Burgos-Vargas R. Primary prevention in rheumatology: the importance of hyperuricemia. Best Pract Res Clin Rheum 2004;18:111–24.10.1016/j.berh.2004.01.001Search in Google Scholar

2. Liu B, Wang T, Zhao HN, Yue WW, Yu HP, Liu CX, et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health 2011;11:2965–6.Search in Google Scholar

3. White JS. Comment on: new insights into the epidemiology of gout. Rheumatology (Oxford) 2010;49:613–4; author reply 4.10.1093/rheumatology/kep349Search in Google Scholar

4. Richette P, Bardin T. Gout. Lancet 2010;375:318–28.10.1016/S0140-6736(09)60883-7Search in Google Scholar

5. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223.10.1016/j.rdc.2014.01.001Search in Google Scholar PubMed PubMed Central

6. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur Heart J 2006;27:1174–81.10.1093/eurheartj/ehi879Search in Google Scholar PubMed PubMed Central

7. Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases–where worlds meet. N Engl J Med 2010;363:1196–8.10.1056/NEJMp1002024Search in Google Scholar PubMed

8. Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, et al. Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013;93:153–8.10.1038/clpt.2012.209Search in Google Scholar PubMed PubMed Central

9. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545–9.10.1136/ard.57.9.545Search in Google Scholar PubMed PubMed Central

10. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356–60.10.1002/art.10511Search in Google Scholar PubMed

11. Silver MA. The natriuretic peptide system: kidney and cardiovascular effects. Curr Opin Nephrol Hypertens 2006;15:14–21.10.1097/01.mnh.0000199008.49176.37Search in Google Scholar PubMed

12. Dries DL. Process matters: emerging concepts underlying impaired natriuretic peptide system function in heart failure. Circ Heart Fail 2011;4:107–10.10.1161/CIRCHEARTFAILURE.111.960948Search in Google Scholar

13. Karjalainen AH, Ruskoaho H, Vuolteenaho O, Heikkinen JE, Backstrom AC, Savolainen MJ, et al. Effects of estrogen replacement therapy on natriuretic peptides and blood pressure. Maturitas 2004;47:201–8.10.1016/S0378-5122(03)00279-2Search in Google Scholar

14. Zhang J, Meng Z, Zhang Q, Liu L, Song K, Tan J, et al. Gender impact on the correlations between subclinical thyroid dysfunction and hyperuricemia in Chinese. Clin Rheum 2016;35:143–9.10.1007/s10067-015-2867-4Search in Google Scholar

15. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 1999;354:650.10.1016/S0140-6736(99)92381-4Search in Google Scholar

16. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women – the Third National Health and Nutrition Examination Survey. Arthritis Res Ther 2008;10:R116.10.1186/ar2519Search in Google Scholar PubMed PubMed Central

17. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 2014;16:14–26.10.1111/jch.12237Search in Google Scholar PubMed PubMed Central

18. 1993 Guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. Hypertension 1993;22:392–403.10.1161/01.HYP.22.3.392Search in Google Scholar

19. Kerner W, Bruckel J. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2014;122:384–6.10.1055/s-0034-1366278Search in Google Scholar PubMed

20. Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. [Chinese guidelines on prevention and treatment of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35: 390–419.Search in Google Scholar

21. Kuo CC, Weaver V, Fadrowski JJ, Lin YS, Guallar E, Navas-Acien A. Arsenic exposure, hyperuricemia, and gout in US adults. Environ Int 2015;76:32–40.10.1016/j.envint.2014.11.015Search in Google Scholar PubMed

22. Peng H, Ding J, Peng Y, Zhang Q, Xu Y, Chao X, et al. Hyperuricemia and microalbuminuria are separately and independently associated with prehypertension among Chinese Han women. Metab Syndr Relat Disord 2012;10:202–8.10.1089/met.2011.0119Search in Google Scholar PubMed

23. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl. 1):S1–266.Search in Google Scholar

24. Cheung E, Tsang S, Bow C, Soong C, Yeung S, Loong C, et al. Bone loss during menopausal transition among southern Chinese women. Maturitas 2011;69:50–6.10.1016/j.maturitas.2011.01.010Search in Google Scholar PubMed

25. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54: 2688–96.10.1002/art.22014Search in Google Scholar PubMed

26. Tzikas S, Keller T, Wild PS, Schulz A, Zwiener I, Zeller T, et al. Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study. Clin Chem Lab Med 2013;51:1125–33.10.1515/cclm-2012-0541Search in Google Scholar PubMed

27. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 2011;63:102–10.10.1002/acr.20344Search in Google Scholar PubMed PubMed Central

28. Then C, Kowall B, Lechner A, Meisinger C, Heier M, Koenig W, et al. Plasma MR-proANP levels are associated with carotid intima-media thickness in the general community: the KORA F4 study. Atherosclerosis 2013;230:235–41.10.1016/j.atherosclerosis.2013.07.047Search in Google Scholar PubMed

29. Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metabol 2012;97:638–45.10.1210/jc.2011-2425Search in Google Scholar PubMed PubMed Central

30. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 2005;16:469–77.10.1016/j.tem.2005.10.007Search in Google Scholar PubMed

31. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrine Rev 2006;27:47–72.10.1210/er.2005-0014Search in Google Scholar PubMed

32. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992;86:1081–8.10.1161/01.CIR.86.4.1081Search in Google Scholar

33. Theilig F, Wu Q. ANP-induced signaling cascade and its implications in renal pathophysiology. Am J Phys Renal Physiol 2015;308:F1047–55.10.1152/ajprenal.00164.2014Search in Google Scholar PubMed PubMed Central

34. Zhou Y, Wu Q. Role of corin and atrial natriuretic peptide in preeclampsia. Placenta 2013;34:89–94.10.1016/j.placenta.2012.11.016Search in Google Scholar PubMed PubMed Central

35. Song W, Wang H, Wu Q. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 2015;569:1–6.10.1016/j.gene.2015.06.029Search in Google Scholar PubMed PubMed Central

36. Lynch AI, Claas SA, Arnett DK. A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep 2009;11:35–42.10.1007/s11906-009-0008-7Search in Google Scholar PubMed

37. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 2006;48:499–505.10.1016/j.jacc.2005.12.081Search in Google Scholar PubMed

38. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004;35:814–8.10.1161/01.STR.0000119381.52589.ABSearch in Google Scholar PubMed

39. Barbato E, Bartunek J, Mangiacapra F, Sciarretta S, Stanzione R, Delrue L, et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol 2012;59:1763–70.10.1016/j.jacc.2012.02.017Search in Google Scholar PubMed

40. Rosenzweig A, Seidman CE. Atrial natriuretic factor and related peptide hormones. Ann Rev Biochem 1991;60:229–55.10.1146/annurev.bi.60.070191.001305Search in Google Scholar PubMed

41. Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 2013;1832:2442–50.10.1016/j.bbadis.2012.12.014Search in Google Scholar PubMed

42. Vaz Perez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, et al. The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2010;141:39–43.10.1016/j.ijcard.2008.11.146Search in Google Scholar PubMed

43. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I epidemiologic follow-up study. Am J Epidemiol 1995;141:637–44.10.1093/oxfordjournals.aje.a117479Search in Google Scholar PubMed

44. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7–13.10.7326/0003-4819-131-1-199907060-00003Search in Google Scholar PubMed

Received: 2016-6-9

Accepted: 2016-11-7

Published Online: 2017-1-11

Published in Print: 2017-7-26

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/cclm-2016-0503

Keywords for this article

Chinese; cross-sectional study; hyperuricemia; plasma proANP; serum uric acid